Rapid Dose Therapeutics Income Statement

Financials in millions CAD. Fiscal year is March - February.

Millions CAD. Fiscal year is Mar - Feb.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Feb '26 Feb 28, 2026	Feb '25 Feb 28, 2025	Feb '24 Feb 29, 2024	Feb '23 Feb 28, 2023	Feb '22 Feb 28, 2022
Revenue	2.77	2.09	1.02	0.72	1.75
Revenue Growth (YoY)	33.00%	104.34%	42.06%	-59.00%	131.98%
Cost of Revenue	1.41	0.91	0.46	0.36	0.41
Gross Profit	1.36	1.18	0.56	0.36	1.34
Selling, General & Admin	2.67	3.55	2.45	2.46	2.99
Research & Development	0.03	0.15	0.43	0.09	0.36
Operating Expenses	3.53	5.35	3.65	3.9	5.65
Operating Income	-2.17	-4.17	-3.09	-3.54	-4.3
Interest Expense	-1.22	-1.23	-0.66	-0.26	-0.13
Interest & Investment Income	-	-	-	-	0
Currency Exchange Gain (Loss)	-	-	-	-0	0.02
Other Non Operating Income (Expenses)	-	-	-	-	0.01
EBT Excluding Unusual Items	-3.39	-5.4	-3.75	-3.81	-4.4
Impairment of Goodwill	-	-	-	-	-4.08
Other Unusual Items	-	-	-0.56	-	-
Pretax Income	-3.39	-5.4	-4.31	-3.81	-8.49
Net Income	-3.39	-5.4	-4.31	-3.81	-8.49
Net Income to Common	-3.39	-5.4	-4.31	-3.81	-8.49
Shares Outstanding (Basic)	133	125	105	103	100
Shares Outstanding (Diluted)	133	125	105	103	100
Shares Change (YoY)	6.73%	18.68%	1.50%	3.19%	28.83%
EPS (Basic)	-0.03	-0.04	-0.04	-0.04	-0.08
EPS (Diluted)	-0.03	-0.04	-0.04	-0.04	-0.08
Free Cash Flow	-0.27	-1.15	-2.29	-0.86	-3.04
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.01	-0.03
Gross Margin	49.15%	56.59%	55.21%	49.67%	76.76%
Operating Margin	-78.29%	-200.07%	-302.45%	-493.36%	-245.55%
Profit Margin	-122.23%	-259.18%	-422.03%	-530.42%	-484.47%
Free Cash Flow Margin	-9.78%	-55.27%	-224.91%	-120.27%	-173.52%
EBITDA	-1.66	-3.95	-2.75	-3.2	-3.82
EBITDA Margin	-59.78%	-189.66%	-269.93%	-	-218.31%
D&A For EBITDA	0.51	0.22	0.33	0.34	0.48
EBIT	-2.17	-4.17	-3.09	-3.54	-4.3
EBIT Margin	-78.29%	-200.07%	-	-	-245.55%